Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.

Front Immunol · 2022 · PMC9388930 · PMID 35990690

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

EGFR-mutated patients with lower PD-L1 expression showed a trend towards a longer OS after receiving ICIs.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, contrary to expectations, our results displayed that the overall or major EGFR-mutated patients with higher PD-L1 expression showed a trend towards a shorter OS after receiving ICIs, although the results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.